Rare cannabinoids that cannot practically be extracted from hemp will instead be manufactured by specially-created micro-organisms.
A new partnership between Cronos Group, a Canadian vertically integrated cannabis company, and Ginkgo Bioworks, a Massachusetts-based bioengineering specialist, will see Ginkgo modify the DNA of yeast so that it can produce cannabinoids in a fermentation process.
They include cannabidiolic acid (CBDA), a substance naturally present in the hemp plant, which is then turned into cannabidiol (CBD) when its chemical composition is altered through heating.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
This report will enable you to identify pricing differences and the range of pricing for product types across different markets, understand possible reasoning for pricing differences across different markets, and identify price points for strategy development and price setting.